In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a price target of $26.00. The company ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Regeneron Pharmaceuticals just hit a new 52-week low after UBS dropped its price target and slapped on a neutral rating.

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Well, we could find out. Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million ...

Leerink Partners on Friday upgraded Fulcrum Therapeutics, Inc. (NASDAQ:FULC) to Outperform from Market Perform, and raised the stock’s price target to $12 per share from $4. The analyst cited a ...

A biotech future built on data: Regeneron’s acquisition of 23andMe blurs the line between pharmaceutical innovation and genetic surveillance. Unsplash+ “We are pleased to have reached a ...